The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Last updated: July 28, 2024
Sponsor: Wonju Severance Christian Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hemorrhage

Treatment

Nafamostat Mesylate

Clinical Study ID

NCT05874674
CR122018
  • Ages 18-99
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Comparison nafamostat and low molecular weight heparin among dialysis patients

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months)receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent usersreceived major surgery within one month

Exclusion

Exclusion Criteria:

  • cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Nafamostat Mesylate
Phase:
Study Start date:
December 01, 2023
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Yonsei Unviersity Wonju College of Medicin

    Wonju, Kangwondo 26426
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.